FENNEC PHARMACEUTICALS INC.
FENCNasdaq
$10.50
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +17.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$373.3M
Enterprise Value
$333.1M
P/E
—
P/S
7.3
P/B
9.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$51.0M
Net Income (TTM)
-$9.7B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-11.0%
Net Margin
-19097.7%
ROE
-25851.7%
ROIC
—
Debt / Equity
—
Net Cash
$40.2M
Return 1Y
+20.0%
Company profile
Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
- CEO
- Rostislav C. Raykov
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- North Carolina
- Website
- fennecpharma.com
Management & directors
- Andrade RobertCHIEF FINANCIAL OFFICER
- Cioffi Christiana MarieChief Strategy Officer
- Evans Terry LChief Commercial Officer
- Hackman Jeffrey S.Chief Executive Officer
- Sayad Pierre SargisChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
FENC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.1M↑ +72.6%
Diluted EPS$0.01↓ -125.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $200,000.00 | — | $1.5M | $21.3M | $47.5M | $44.6M |
| Gross profit | — | — | $1.4M | $20.0M | — | — |
| Operating income | -$17.9M | -$17.2M | -$22.6M | -$12.8M | $2.6M | -$6.3M |
| Net income | -$18.1M | -$17.3M | -$23.7M | -$16.0B | -$436.0M | -$9.7B |
| Diluted EPS | -$0.76 | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 |
| Operating cash flow | -$15.6M | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | 94.4% | 94.1% | — | — |
| Operating margin | -8942.5% | — | -1471.6% | -60.1% | 5.4% | -14.1% |
| Net margin | -9054.5% | — | -1544.9% | -75498.8% | -917.2% | -21820.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $7.0M | $7.9M | $8.8M | $9.7M | $12.5M | $13.8M | $15.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.0M | -$5.2M | -$934,000.00 | -$808,000.00 | -$2.7M | -$189,000.00 | -$2.6M | -$119,000.00 |
| Net income | -$5.6M | -$5.7M | -$437.5M | -$1.2M | -$3.2M | -$638,000.00 | -$9.7B | $201,000.00 |
| Diluted EPS | -$0.20 | -$0.21 | -$0.02 | -$0.04 | -$0.11 | -$0.02 | -$0.17 | $0.01 |
| Operating cash flow | -$8.4M | -$2.2M | -$1.5M | -$4.3M | -$3.7M | $1.5M | -$6.0M | $2.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -69.4% | -74.6% | -11.8% | -9.2% | -28.3% | -1.5% | -18.5% | -0.8% |
| Net margin | -76.5% | -82.2% | -5521.1% | -13.3% | -32.7% | -5.1% | -70668.8% | 1.3% |
Company news
Jul 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Raykov Rosty | Sale | 9,599 | $10.41 | $99,925.59 | filing |
| 2026-07-01 | Raykov Rosty | Option exercise | 15,597 | $2.45 | $38,212.65 | filing |
| 2026-07-01 | Raykov Rosty | Award | 2,778 | $0.00 | $0.00 | filing |
| 2026-06-30 | Andrade Robert· CHIEF FINANCIAL OFFICER | Award | 1,703 | $0.00 | $0.00 | filing |
| 2026-06-30 | Cioffi Christiana Marie· Chief Strategy Officer | Award | 156 | $0.00 | $0.00 | filing |
| 2026-06-30 | Hackman Jeffrey S.· Chief Executive Officer | Award | 1,159 | $0.00 | $0.00 | filing |
| 2026-06-30 | Evans Terry L· Chief Commercial Officer | Award | 168 | $0.00 | $0.00 | filing |
| 2026-06-30 | Sayad Pierre Sargis· Chief Medical Officer | Award | 168 | $0.00 | $0.00 | filing |
| 2026-06-01 | Raykov Rosty | Sale | 9,747 | $9.62 | $93,766.14 | filing |
| 2026-06-01 | Raykov Rosty | Option exercise | 15,597 | $2.45 | $38,212.65 | filing |
| 2026-05-31 | Sayad Pierre Sargis· Chief Medical Officer | Award | 168 | $0.00 | $0.00 | filing |
| 2026-05-31 | Raykov Rosty | Award | 2,778 | $0.00 | $0.00 | filing |
| 2026-05-31 | Cioffi Christiana Marie· Chief Strategy Officer | Award | 156 | $0.00 | $0.00 | filing |
| 2026-05-31 | Evans Terry L· Chief Commercial Officer | Award | 168 | $0.00 | $0.00 | filing |
| 2026-05-31 | Hackman Jeffrey S.· Chief Executive Officer | Award | 1,159 | $0.00 | $0.00 | filing |
| 2026-05-31 | Andrade Robert· CHIEF FINANCIAL OFFICER | Award | 1,703 | $0.00 | $0.00 | filing |
| 2026-05-11 | RALLIS CHRIS A | Sale | 8,346 | $7.04 | $58,755.84 | filing |
| 2026-05-11 | RALLIS CHRIS A | Option exercise | 14,344 | $2.44 | $34,999.36 | filing |
| 2026-05-01 | Raykov Rosty | Sale | 10,781 | $6.47 | $69,753.07 | filing |
| 2026-05-01 | Raykov Rosty | Option exercise | 15,598 | $2.45 | $38,215.10 | filing |
| 2026-04-30 | Hackman Jeffrey S.· Chief Executive Officer | Option exercise | 1,159 | $0.00 | $0.00 | filing |
| 2026-04-30 | Andrade Robert· CHIEF FINANCIAL OFFICER | Option exercise | 1,703 | $0.00 | $0.00 | filing |
| 2026-04-30 | Sayad Pierre Sargis· Chief Medical Officer | Option exercise | 168 | $0.00 | $0.00 | filing |
| 2026-04-30 | Raykov Rosty | Option exercise | 2,778 | $0.00 | $0.00 | filing |
| 2026-04-30 | Evans Terry L· Chief Commercial Officer | Option exercise | 168 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.